What’s New for Hatch-Waxman Litigation: Exploring Trends, Updates, and Critical Issues
As the COVID-19 crisis stretches into its third year, brands and generic drug companies will likely see the impact of continued regulatory developments in the Hatch-Waxman space. Moreover, recent notable cases further reveal key takeaways and unresolved issues which drug companies should be wary of. Among the salient developments involve changes in venue for a Hatch-Waxman Act case — highlighting the need for concerned practitioners to stay close to the venue issue as it remains to be a focus of the Federal courts. In this program, a panel of key thought leaders and practitioners will offer an in-depth look at the critical developments and issues surrounding Hatch-Waxman litigation. This course will provide helpful insights to help your company deal with patent challenges.